title: Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1.
abstract: Background. This retrospective study aimed to assess the efficacy and toxicities of second-line chemotherapy with irinotecan, leucovorin, and 5-fluorouracil (5-FU) in metastatic gastric cancer (MGC) patients previously treated with docetaxel and S-1 with or without oxaliplatin (DS/DOS). Patients and Methods. We reviewed the data of patients who had previously been treated with first-line DS/DOS and received biweekly irinotecan-based chemotherapy (FOLFIRI/IFL) between October 2004 and November 2011. Results. A total of 209 cycles were administered to 35 patients, with a median of 4 (range, 1-22) cycles each. The overall response rate in 29 response-assessable patients was 17.2%, including 2 complete and 3 partial responses. The median progression-free and overall survivals were 3.81 (95% confidence interval [CI], 1.82-5.80) months and 6.24 (95% CI, 1.44-11.04) months, respectively. The major grade 3/4 toxicity was neutropenia (8.6%). Conclusion. FOLFIRI/IFL chemotherapy showed modest antitumour activity and tolerable toxicities in DS/DOS-treated MGC patients.
authors.affiliation: Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea.
authors.forename: Joo Young
authors.initials: JY
authors.lastname: Jung
authors.affiliation: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
authors.forename: Min-Hee
authors.initials: MH
authors.lastname: Ryu
authors.affiliation: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
authors.forename: Baek-Yeol
authors.initials: BY
authors.lastname: Ryoo
authors.affiliation: Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea.
authors.forename: Boram
authors.initials: B
authors.lastname: Han
authors.affiliation: Department of Surgery, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea.
authors.forename: Ji Woong
authors.initials: JW
authors.lastname: Cho
authors.affiliation: Department of Surgery, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea.
authors.forename: Man Sup
authors.initials: MS
authors.lastname: Lim
authors.affiliation: Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea.
authors.forename: Hyun
authors.initials: H
authors.lastname: Lim
authors.affiliation: Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea.
authors.forename: Ho Suk
authors.initials: HS
authors.lastname: Kang
authors.affiliation: Department of Radiology, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea.
authors.forename: Min-Jeong
authors.initials: MJ
authors.lastname: Kim
authors.affiliation: Department of Radiology, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea.
authors.forename: Hong Il
authors.initials: HI
authors.lastname: Ha
authors.affiliation: Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea.
authors.forename: Hunho
authors.initials: H
authors.lastname: Song
authors.affiliation: Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea.
authors.forename: Jung Han
authors.initials: JH
authors.lastname: Kim
authors.affiliation: Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea.
authors.forename: Hyeong Su
authors.initials: HS
authors.lastname: Kim
authors.affiliation: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
authors.forename: Yoon-Koo
authors.initials: YK
authors.lastname: Kang
authors.affiliation: Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea.
authors.forename: Dae Young
authors.initials: DY
authors.lastname: Zang
references.citation: Ann Oncol. 2007 May;18(5):886-91
references.pmid: 17298958
references.citation: Eur J Cancer. 2011 Oct;47(15):2306-14
references.pmid: 21742485
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2903-9
references.pmid: 16782930
references.citation: J Clin Oncol. 2012 May 1;30(13):1513-8
references.pmid: 22412140
references.citation: J Clin Oncol. 2006 Nov 1;24(31):4991-7
references.pmid: 17075117
references.citation: N Engl J Med. 2008 Jan 3;358(1):36-46
references.pmid: 18172173
references.citation: Lancet Oncol. 2015 May;16(5):499-508
references.pmid: 25877855
references.citation: Br J Cancer. 1999 Mar;79(9-10):1522-30
references.pmid: 10188901
references.citation: Med Oncol. 2014 Sep;31(9):153
references.pmid: 25099765
references.citation: Br J Cancer. 2006 Jun 19;94(12):1803-8
references.pmid: 16773074
references.citation: Cancer Chemother Pharmacol. 2009 Feb;63(3):509-16
references.pmid: 18481067
references.citation: Lancet Oncol. 2014 Oct;15(11):1224-35
references.pmid: 25240821
references.citation: J Clin Oncol. 2004 Jun 15;22(12):2395-403
references.pmid: 15197201
references.citation: Lancet Oncol. 2008 Mar;9(3):215-21
references.pmid: 18282805
references.citation: Cancer Chemother Pharmacol. 2013 Feb;71(2):481-8
references.pmid: 23192279
references.citation: Lancet Oncol. 2013 May;14 (6):481-9
references.pmid: 23594787
references.citation: Eur J Surg Oncol. 2010 Dec;36(12):1172-9
references.pmid: 20888167
references.citation: Cancer Chemother Pharmacol. 2013 Sep;72 (3):629-35
references.pmid: 23881212
references.citation: Ann Oncol. 2013 Nov;24(11):2850-4
references.pmid: 23942775
references.citation: Lancet Oncol. 2014 Jan;15(1):78-86
references.pmid: 24332238
references.citation: J Clin Oncol. 2002 Dec 1;20(23):4543-8
references.pmid: 12454110
references.citation: Br J Cancer. 2008 Nov 4;99(9):1402-7
references.pmid: 18971936
references.citation: Br J Cancer. 2011 Aug 9;105(4):505-12
references.pmid: 21792201
references.citation: Ann Oncol. 2009 Apr;20(4):666-73
references.pmid: 19153121
references.citation: Lancet. 2014 Jan 4;383(9911):31-9
references.pmid: 24094768
references.citation: Cancer Chemother Pharmacol. 2009 Oct;64(5):877-83
references.pmid: 19190908
references.citation: Eur J Cancer. 2014 May;50(8):1437-45
references.pmid: 24560487
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4779-86
references.pmid: 17947725
references.citation: Gastric Cancer. 2016 Apr;19(2):579-85
references.pmid: 25997815
references.citation: Am J Clin Oncol. 2010 Dec;33(6):572-6
references.pmid: 20042971
references.citation: J Clin Oncol. 1997 Jan;15(1):261-7
references.pmid: 8996151
references.citation: J Exp Clin Cancer Res. 2013 Sep 17;32:67
references.pmid: 24330513
references.citation: Am J Clin Oncol. 2008 Apr;31(2):151-6
references.pmid: 18391599